MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
The FDA determined that the data presented in a 2022 color additive petition show that this ingredient causes cancer in male laboratory rats exposed to high levels of FD&C Red No. 3 because of a hormonal mechanism that occurs in male rats
The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”
Modernization and supply chain diversity drive new growth
He has 35+ years of experience in understanding of business and products, analytical ability, eye for detail and computer literacy and knowledge of recent trends.
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
This facility underwent an inspection from 15th to 19th July 2024 and has been classified as Voluntary Action Indicated
Showcases specialty and sustainable materials for healthcare at Medtec China 2024
AMR poses a critical threat to global public health undermining decades of progress made in the field of modern medicine
The company will take all necessary steps to work with USFDA towards earliest remediation of the above facility
Subscribe To Our Newsletter & Stay Updated
